Amenorrhea and resumption of menstruation after uterine artery embolization for fibroids.

Department of Radiology, Saiseikai Shiga Hospital, Ritto, Shiga, Japan.
International Journal of Gynecology & Obstetrics (Impact Factor: 1.84). 09/2008; 103(3):217-21. DOI: 10.1016/j.ijgo.2008.07.010
Source: PubMed

ABSTRACT To determine whether women will experience permanent amenorrhea following uterine artery embolization for fibroids, and whether rates of onset differ in the long term according to age at the time of the procedure.
Over 77 months, 211 consecutive eligible women were grouped by age (group A, <40 years [n=39]; group B, 40-44 years [n=98]; and group C, > or =45 years [n=74]) and the cumulative rates of onset of permanent amenorrhea were compared between the groups.
The likelihood of incurring permanent amenorrhea was significantly higher in group C. The cumulative rates in groups A, B, and C were 0%, 1.4%, and 19.7% at 3 years and 0%, 11.2%, and 40.4% at 6 years.
The rates of onset of permanent amenorrhea changed over time and differed according to age at the time of the procedure, with little likelihood of permanent amenorrhea at 6 years for women younger than 40 years at the time of the procedure.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Uterine leiomyomas (fibroids) are the most common tumors in women of reproductive age and a cause of significant morbidity in this patient population. Depending on the fibroid location, they can be the cause of a variety of symptoms, such as abnormal uterine bleeding, constipation, urinary frequency, and pain. Historically, hysterectomy has been the primary treatment option, and uterine fibroids remain the leading cause for hysterectomy in the United States. However, women who do not wish to undergo hysterectomy now have a variety of less invasive options available, including uterine artery embolization. This article discusses uterine artery embolization as well as some of the other treatment strategies for symptomatic uterine fibroids. In many situations, there may be no single best treatment option but several viable alternatives. Each option is discussed with consideration of outcomes, complications, and, when possible, cost-effectiveness. The recommendations in this article are the result of evidence-based consensus of the ACR Appropriateness Criteria® Expert Panel on Interventional Radiology.
    Journal of the American College of Radiology: JACR 04/2011; 8(4):228-34.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether uterine fibroid embolization before the age of 45 years advances the timing of natural menopause. Prospective cohort study. University tertiary-care center. Forty-three regularly cycling women aged 35-44 years who underwent embolization and 43 age-matched control subjects. Annual assessments of menopausal status using prospectively recorded menstrual diaries and hormonal (serum FSH and E(2)) and ultrasound measures (ovarian volume and antral follicle count). Women were followed for 7 years or until they reached menopause. Age at menopause as computed by subtracting the date of birth from the exact date of the last menstrual period. Over the study period, 9 patients (25%) and 12 control subjects (33%) became menopausal, 19 patients (53%) and 18 control subjects (50%) entered the menopausal transition (irregular cycles), and 8 patients (22%) and 6 control subjects (17%) continued to menstruate regularly. Mean menopausal age in the embolization group (48.94 ± 2.48 years) was not significantly different from that in the control group (49.52 ± 1.25 years). There was no significant difference of menopause occurrence between the groups. Longitudinal changes in hormonal and ultrasound measures were similar for the two groups. This long-term follow-up study found no evidence for fibroid embolization advancing the timing of menopause in women before the age of 45 years.
    Fertility and sterility 07/2011; 96(4):980-4. · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 27-year-old woman had massive genital bleeding after an artificial abortion. Color Doppler ultrasonography showed a hypervascular mass. Hysteroscopy revealed a placental polyp. Serum hemoglobin level was decreased to 7.7 g/dl. Although uterine artery embolization (UAE) followed by hysteroscopic resection has been used for treatment of a placental polyp, UAE may not be an ideal option for patients with intent for future pregnancy because of the risk of ovarian function failure. This report presents a case of a placental polyp managed successfully with intracervical injection of prostaglandin F2α, as an alternative UAE, followed by hysteroscopic resection.
    Reproductive Medicine and Biology 11(2).